- Home
- MGNI vs IMCR Comparison
MGNI vs IMCR Comparison
Compare MGNI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- IMCR
- Stock Information
- Founded
- MGNI 2007
- IMCR 2008
- Country
- MGNI United States
- IMCR United Kingdom
- Employees
- MGNI N/A
- IMCR N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGNI Technology
- IMCR Health Care
- Exchange
- MGNI Nasdaq
- IMCR Nasdaq
- Market Cap
- MGNI 1.7B
- IMCR 1.7B
- IPO Year
- MGNI N/A
- IMCR 2021
- Fundamental
- Price
- MGNI $12.94
- IMCR $32.93
- Analyst Decision
- MGNI Strong Buy
- IMCR Buy
- Analyst Count
- MGNI 11
- IMCR 14
- Target Price
- MGNI $16.95
- IMCR $74.75
- AVG Volume (30 Days)
- MGNI 1.3M
- IMCR 267.8K
- Earning Date
- MGNI 11-07-2024
- IMCR 11-05-2024
- Dividend Yield
- MGNI N/A
- IMCR N/A
- EPS Growth
- MGNI N/A
- IMCR N/A
- EPS
- MGNI N/A
- IMCR N/A
- Revenue
- MGNI $649,216,000.00
- IMCR $280,914,000.00
- Revenue This Year
- MGNI $0.26
- IMCR $25.60
- Revenue Next Year
- MGNI $10.75
- IMCR $10.63
- P/E Ratio
- MGNI N/A
- IMCR N/A
- Revenue Growth
- MGNI 7.50
- IMCR 27.95
- 52 Week Low
- MGNI $6.46
- IMCR $29.72
- 52 Week High
- MGNI $15.92
- IMCR $76.98
- Technical
- Relative Strength Index (RSI)
- MGNI 54.59
- IMCR 52.76
- Support Level
- MGNI $12.35
- IMCR $31.10
- Resistance Level
- MGNI $13.11
- IMCR $35.47
- Average True Range (ATR)
- MGNI 0.42
- IMCR 1.49
- MACD
- MGNI 0.11
- IMCR 0.17
- Stochastic Oscillator
- MGNI 63.58
- IMCR 51.98
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.